CN-121610416-B - Klebsiella aerogenes HW2024 and application thereof in preparation of medicines for treating allergic rhinitis

CN121610416BCN 121610416 BCN121610416 BCN 121610416BCN-121610416-B

Abstract

The invention discloses Klebsiella oxytoca HW2024 and application thereof in preparing medicines for treating allergic rhinitis, wherein the preservation number is CCTCC NO: M20252524. The Klebsiella aerogenes is symbiotic bacteria, is relatively safe and easy to obtain, can greatly reduce the treatment cost of AR patients, provides new treatment options for AR treatment, and is convenient in administration route, easy to operate and convenient for patients to use.

Inventors

LIU ZHENG
HU DANQING
WANG HAI

Assignees

华中科技大学同济医学院附属同济医院

Dates

Publication Date: 20260505
Application Date: 20260126

Claims (7)

1. Klebsiella aerogenes (Klebsiella aerogenes) HW2024 has a preservation number of CCTCC NO: M20252524.
2. Use of klebsiella aerogenes HW2024 as claimed in claim 1 for the preparation of a medicament for the treatment of allergic rhinitis.
3. A pharmaceutical preparation for treating allergic rhinitis is characterized by comprising an effective amount of Klebsiella aerogenes HW2024 as claimed in claim 1 and pharmaceutically acceptable auxiliary materials.
4. The pharmaceutical preparation according to claim 3, wherein the auxiliary materials are physiological saline, glucose, vitamin C and amino acid.
5. The pharmaceutical preparation according to claim 3 or 4, wherein the pharmaceutical preparation is a nasal drop or a spray or a rinse.
6. The pharmaceutical preparation for treating AR according to claim 5, wherein the spray preparation is an aerosol, a spray or a suspension.
7. The pharmaceutical preparation for treating AR according to claim 3, wherein the Klebsiella aerogenes HW2024 has a content of 10 6 -10 8 CFU/mL.

Description

Klebsiella aerogenes HW2024 and application thereof in preparation of medicines for treating allergic rhinitis Technical Field The invention relates to the field of biological medicine, in particular to Klebsiella aerogenes HW2024 and application thereof in preparing medicines for treating allergic rhinitis. Background Allergic Rhinitis (AR) is a common chronic inflammatory disease of the upper airways with prevalence of up to 20-30%. It not only severely threatens the health of the patient, impairs the quality of life of the patient, but also is an important risk factor for causing lower respiratory diseases and psychological mental disorders. However, the clinical therapeutic effect of AR is far from satisfactory, and the discussion of pathogenesis and clinical transformation medical research thereof still can be hot spots and important points of ear, nose, throat, head and neck surgery for a long time. (1) IgE-mast cell-histamine signaling axis plays an important role in AR pathogenesis The former research shows that the production of immunoglobulin E (immunoglobulin E, igE) and the functional regulation thereof are one of the key links of AR pathogenesis, wherein inhaled allergen induces organism to produce antigen-specific IgE, igE is combined with mast cells and basophil surface IgE receptors (Fc epsilon R1) gathered on nasal mucosa to form a sensitized state, when the organism contacts the same allergen again, the allergen is combined with IgE anchored on the surfaces of the mast cells and the basophil, so as to activate the mast cells and the basophil, induce degranulation thereof, release inflammatory mediators such as histamine and type 2 cytokines, the histamine acts on sensory nerve endings of the nasal mucosa and corresponding receptors of vascular endothelium to cause the vascular dilation and gland secretion increase of the nasal mucosa, thereby causing symptoms such as nasal itching, sneeze, waterlike, vascular endothelial cells and the like, and can also induce expression or secretion of adhesion molecules, chemotactic factors, cytokines and the like, recruit and activate immune cells such as basophil granulocytes, basophil and type 2 helper T cells and the like, thereby causing chronic inflammation, and inflammatory cells which are released simultaneously, further causing nasal tissue edema and nasal mucosa edema. Thus, igE-mast cell-histamine signaling axis plays an important role in the development of AR disease, while blocking histamine production or its downstream signaling pathways has a potential therapeutic effect on AR. In fact, histamine receptor antagonists have become one of the common drugs for treating AR clinically, but there are adverse reactions such as nasal bleeding and headache, and a significant part of patients have poor therapeutic effects, so that the metabolic mechanism of histamine needs to be clarified, and a targeted therapeutic target is found based on the mechanisms. (2) Partial histamine metabolic imbalance of nasal mucosa and related to severity of AR disease Histamine is a nitrogen-containing compound that is primarily derived from mast cells, basophils, and platelets. Histamine is produced by L-histidine under the catalysis of L-Histidine Decarboxylase (HDC). And histamine degrading enzymes include histamine N-methyltransferase (HNMT) and diamine oxidase (DAO). HNMT exists in cytoplasm and can be widely expressed in various cells of human body, and DAO is a secreted protein mainly produced by kidney, intestinal tract and placenta, so HMNT and DAO are respectively involved in regulating degradation of intracellular and extracellular histamine. Previous studies have shown that HNMT and DAO in human nasal mucosa all exert histamine degrading effects. Interestingly, nasal mucosa HDC expression levels in AR patients were significantly increased compared to control groups, whereas histamine-degrading enzyme HNMT and DAO expression levels and ability to degrade histamine activity were significantly decreased and correlated with disease severity. Thus, metabolic disorders of nasal mucosa local histamine are closely related to their pathogenesis, and promotion of degradation of nasal mucosa local histamine can be one of the effective means for treating AR. (3) Identification of nasal topical histamine-degrading bacteria In recent years, in the field of food safety, the level of histamine in foods such as dairy products is degraded by the addition of microbial agents such as DAO-producing bacteria, thereby reducing the risk of histamine poisoning in foods and improving symptoms associated with histamine intolerant people. Guarcello et al found that lactobacillus can secrete DAO to degrade histamine in cheese. PASHANGEH et al, 27 of 243 staphylococci identified from goat milk showed the ability to degrade histamine, of which Staphylococcus epidermidis was the strongest. In fact, a large number of bacteria are also colonized in the nasal cavity parts, and studies have